Center News

Six-month drug regimen cuts HIV risk for breastfeeding infants

SCHARP data shows longer nevirapine treatment reduces infection by half for babies with HIV-infected mothers, 75 percent for infants of untreated moms

March 14, 2011
Dr. Deborah Donnell and Dr. Elizabeth Brown

Dr. Deborah Donnell, principal investigator of the HIV Prevention Trials Network, and Dr. Elizabeth Brown, both of VIDD, are the study’s key statisticians.

Photos: courtesy of Dr. Deborah Donnell, and by Rachel Tompa

Giving breastfeeding infants of HIV-infected mothers a daily dose of the antiretroviral drug nevirapine for six months halved the risk of HIV transmission to the infants at age 6 months compared with giving infants the drug daily for six weeks, according to preliminary clinical trial data presented March 2 at the Retroviruses and Opportunistic Infections conference in Boston.

The longer nevirapine regimen achieved a 75 percent reduction in HIV transmission risk through breast milk for the infants of HIV-infected mothers with higher T-cell counts who had not yet begun treatment for HIV.

“Extended breastfeeding reduces infant mortality in places that lack safe, clean water by protecting babies from common childhood diseases because breast milk contains protective antibodies from the mother that formula feeding does not provide,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which funded the trial.

“These findings show that giving the infants of HIV-infected mothers an antiretroviral drug daily for the full duration of breastfeeding safely minimizes the threat of HIV transmission through breast milk while preserving the health benefits of extended breastfeeding,” he said. 

The new findings apply to mothers and infants in developing nations, where infectious diseases such as gastroenteritis and pneumonia often pose a life-threatening risk to very young children. In the U.S., HIV-infected mothers are urged to feed their babies infant formula, not breast milk, because safe and affordable formula is available, infant deaths due to infections are low, and only total avoidance of breastfeeding will completely protect these infants from HIV transmission through breast milk.

The study, led Dr. Hoosen Coovadia of the University of the Witwatersrand in Durban, South Africa, involves more than 1,500 mother-infant pairs in South Africa, Tanzania, Uganda and Zimbabwe. It began in February 2007 and concludes in July 2011. The Vaccine and Infectious Disease Division’s Statistical Center for HIV/AIDS Research & Prevention serves as the trial’s the data management center. Dr. Deborah Donnell, principal investigator of the HIV Prevention Trials Network, and Dr. Elizabeth Brown, both of VIDD, are the study’s key statisticians.

The participating infants received daily nevirapine for the first six weeks after birth. Those infants who remained free of HIV then were assigned at random to receive either daily nevirapine or a placebo until six months after birth or the cessation of breastfeeding, whichever came first. Study investigators compared the rates of HIV infection in the two groups of infants, and evaluated and compared the safety and tolerance of nevirapine in the infants.

The primary analysis of study data found that 2.4 percent of the infants who received six weeks of nevirapine had acquired HIV through breastfeeding by 6 months of age, but only 1.1 percent of the infants who received six months of nevirapine had acquired HIV through breastfeeding by that time—a 54 percent difference. After the preventive nevirapine regimen was discontinued at six months, however, the rate of subsequent HIV transmission via breastfeeding was the same whether the infants had received daily nevirapine for six weeks or six months.

The percentage of infants who experienced serious health problems was nearly the same in both groups (17 percent in the six-week group and 19 percent in the six-month group). The great majority of these problems were infectious diseases not associated with nevirapine, such as diarrhea, malaria or pneumonia. Only 5 percent of the infants in each group had a health problem that required temporarily stopping daily nevirapine.

In addition, the study team analyzed the impact of the longer nevirapine regimen on the mother’s health and antiretroviral treatment. In mothers who had a T-cell count of at least 350 cells per cubic millimeter of blood, but did not yet require antiretroviral therapy according to World Health Organization guidelines, the nevirapine regimen cut HIV transmission through breast milk by 75 percent relative to the six-week regimen.

In infants born to women with lower T-cell counts who received antiretroviral therapy for their own health, viral transmission to infants through breast milk was zero or nearly zero regardless of the duration of infant nevirapine.

HIV transmission through breast milk occurred at the highest rates among infants born to mothers who had a T-cell count lower than 350 cells per cubic millimeter but did not receive antiretroviral therapy even though they qualified for it. However, the difference in HIV transmission rates between the two infant drug regimens was not statistically significant.

The investigators will conduct their final analysis of the study data after all infants have completed 18 months of follow-up this summer.

The study is co-funded by NIAID, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute on Drug Abuse and the National Institute of Mental Health, all part of the National Institutes of Health.

[Adapted from a National Institutes of Health news release]

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.